ClinicalTrials.gg
Not yet recruitingNCT07600021Updated May 20, 2026

A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of SYH2059 Tablets and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by InnovStone Therapeutics Limited. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by InnovStone Therapeutics Limited (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis
03

In context

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

This study's planned enrollment of 156 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

InnovStone Therapeutics Limited is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age ≥ 40 years, regardless of gender;
  • 2. The investigator confirms the clinical diagnosis of IPF in participants based on chest HRCT, surgical lung , or transbronchial lung cryobiopsy (if available) performed during the screening period or within 1 year prior to screening (see Appendix 13.7 for details);
  • 3. FVCpp ≥ 45% during the screening period;
  • 4. -corrected DLCOpp ≥ 25% and \< 90% during the screening period;
  • 5. Received a single stable-dose antifibrotic therapy for at least 12 weeks prior to screening (concurrent use of nintedanib and pirfenidone is prohibited) and will continue after randomization; or had not received stable antifibrotic therapy, or had discontinued such therapy for at least 8 weeks, with no plan to initiate antifibrotic therapy during the trial;
  • 6. Understands the purpose and risks of this study, comprehends and agrees to comply with all study procedures, consents to participate, and provides written .

Exclusion criteria

Exclusion Criteria:

  • 1. Interstitial lung disease other than IPF.
  • 2. Airway obstruction during screening (/FVC \< 0.7), or emphysema greater than pulmonary fibrosis on HRCT.
  • 3. Confirmed or suspected acute exacerbation of IPF within 3 months prior to screening.
  • 4. Investigator judgment that IPF severity showed sustained improvement during the 12 months prior to screening, based on changes in FVC, DLCO and/or HRCT findings.
  • 5. Other respiratory diseases during screening.
  • 6. Severe diseases in any other system (cardiovascular, digestive, neurological, hematological, endocrine) during screening.
  • 7. within 5 years prior to screening (excluding treated basal cell carcinoma of the skin, in situ squamous cell carcinoma of the skin, or carcinoma in situ of the cervix).
  • 8. Any acute infection within 2 weeks prior to screening that has not fully recovered per investigator judgment.
  • 9. Active, unstable or uncontrolled vasculitis within 8 weeks prior to screening.
  • 10. Any acute or chronic active infection during screening.
  • 11. C-SSRS assessment during screening indicating suicidal behavior within the past 2 years (actual attempt, interrupted attempt, aborted attempt, or preparatory acts or gestures), or clinically significant suicidal ideation within 3 months prior to screening or during screening (participant answered "yes" to C-SSRS suicidal ideation question 4 or 5).
  • 12. Treatment with PDE1, PDE3, PDE4, PDE10 inhibitors, or non-selective PDE inhibitors within 4 weeks prior to screening.
  • 13. Use of strong inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of product, or inability to discontinue such agents during the study.
  • 14. Receiving immunomodulatory agents (excluding oral ) for respiratory or pulmonary conditions during screening, or prednisone (or equivalent) at a daily dose > 15 mg.
  • 15. Abnormal hepatic and renal function during screening: , AST > 2.5 × , or > 1.5 × ULN, or \< 30 mL/min/1.73 m².
  • 16. Severe, persistent, uncontrolled hypertension during screening (SBP ≥ 180 mmHg or DBP ≥ 100 mmHg).
  • 17. History of smoking within 3 months prior to screening or unwillingness to abstain from smoking (including e-cigarettes) during the study.
  • 18. to SYH2059 or any , or history of severe drug allergy.
  • 19. Participation in any clinical trial within 4 weeks prior to screening (excluding those not receiving investigational product).
  • 20. Participation in a clinical study of the same target drug and receipt of treatment within 3 months prior to screening.
  • 21. Pregnant or lactating females; fertile females or males unwilling to practice strict throughout the trial and for 3 months after trial completion until the end of the safety follow-up period (including male participants).

Any other conditions deemed inappropriate for trial participation by the investigator.

  • 22. Additional Exclusion Criteria (for PK intensive sampling participants):
  • 23. Previous history of gastrointestinal surgery that may interfere with the PK of the investigational product.
  • 24. Alcohol consumption exceeding 14 units per week within 4 weeks prior to screening.
  • 25. Habitual excessive intake of xanthine- or caffeine-containing foods, beverages, or other substances affecting drug absorption, distribution, metabolism or excretion within 4 weeks prior to screening.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    High-dose group

    SYH2059 tablets were administered twice daily at 6mg after meals for 12 weeks.

    Drug: SYH2059 Tablets

  • Experimental
    Medium-dose group

    SYH2059 tablets were administered twice daily at 3mg after meals for 12 weeks.

    Drug: SYH2059 Tablets

  • Experimental
    Low dose group

    SYH2059 tablets were administered twice daily at 1.5 mg after meals for 12 weeks.

    Drug: SYH2059 Tablets

  • Placebo comparator
    Placebo group

    Placebo tablets were administered twice daily at 1.5 mg after meals for 12 weeks.

    Drug: Placebo

Interventions

  • DrugSYH2059 Tablets

    Take twice daily, about 12 hours apart, after meals, for 12 weeks.

  • DrugPlacebo

    Take twice daily, about 12 hours apart, after meals, for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in FVC from baseline (mL)

    FVC is one of the pulmonary function indicators; FVC values in patients with IPF tend to decrease.

    Time frame: Week 12

Secondary outcomes

  1. Change in FVC from baseline (mL)

    FVC is one of the pulmonary function indicators; FVC values in patients with IPF tend to decrease.

    Time frame: Week 2,4,8

  2. Change in FVCpp from baseline

    Time frame: Week 12

  3. Proportion of participants with an absolute decrease in FVCpp >10% from baseline

    Time frame: Week 12

  4. Proportion of participants with no decrease in FVCpp from baseline

    Time frame: Week 12

  5. Adjusted change in DLCOpp from baseline

    Time frame: Week 12

  6. Change from baseline in L-PF scale score

    The L-PF questionnaire is used to assess patients' symptoms. It consists of 21 items covering two main domains: the Symptom Module and the Impact Module. Higher scores indicate more severe symptoms and poorer quality of life.

    Time frame: Week 12

  7. Changes in IPF symptoms (cough, dyspnea, fatigue) assessed by VAS from baseline

    The Visual Analogue Scale (VAS) is a commonly used clinical tool for assessing the intensity of subjective symptoms. It typically consists of a 0 - 10 cm line segment, where 0 indicates no symptoms and 10 indicates the most severe symptoms.

    Time frame: Week 12

  8. Incidence and severity of adverse events

    Time frame: Week 13

  9. Changes in C-SSRS over time during the trial

    The Columbia Suicide Severity Rating Scale (C-SSRS) is an internationally recognized standardized tool for suicide risk assessment. It systematically evaluates suicidal ideation , suicidal behavior and self-injurious behavior. Suicidal ideation is graded in severity on a 1 -5 scale, with higher scores indicating stronger suicidal ideation.

    Time frame: Week 13

  10. Plasma concentrations of sparsely sampled participants pre-dose and 2 hours post-dose on Day 14 and Day 84

    Time frame: Week 2,12

  11. PK parameters after the first dose in intensively sampled participants: Cmax.

    Time frame: Day 1

  12. PK parameters after the first dose in intensively sampled participants: AUC0-12.

    Time frame: Day 1

  13. PK parameters after the first dose in intensively sampled participants: Tmax.

    Time frame: Day 1

  14. PK parameters after multiple doses in intensively sampled participants: Ctau,ss.

    Time frame: Week 1,2

  15. PK parameters after multiple doses in intensively sampled participants: Cmax,ss

    Time frame: Week 1,2

  16. PK parameters after multiple doses in intensively sampled participants: Cmin,ss.

    Time frame: Week 1,2

  17. PK parameters after multiple doses in intensively sampled participants: AUC0-tau,ss.

    Time frame: Week 1,2

  18. PK parameters after multiple doses in intensively sampled participants: Tmax,ss.

    Time frame: Week 1,2

  19. Changes in blood biomarkers from baseline.

    Time frame: Week 4,8,12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2027, 16 months later.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 16 months is below that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 20, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Dec 30, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07600021
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion